Retour aux projets

18533.1 PFLS-LS

Development of next-generation antibody drug conjugates for the treatment of lung cancer and multiple myeloma

Résumé

Development of next-generation antibody drug conjugates for the treatment of lung cancer and multiple myeloma

Textes supplémentaires

Abstract

NBE-Therapeutics has developed novel next-generation homogeneous antibody drug conjugates (ADCs)|with proven efficacy in preclinical models of solid tumors, like lung and breast cancer, and hematological|tumors, particularly in multiple myeloma. The goal of the project is to generate optimized ADC lead candidates from early candidates which will be guided by a rigorous assessment of the developability profiles of the ADCs. It will include the development of advanced analytical assays and will lead to novel and optimized ADC candidates for clinical development.

Participants

Ulf Grawunder

Wirtschaftspartner

ulf.grawunder@nbe-therapeutics.com

NBE-Therapeutics GmbH Ulf Grawunder Hochbergerstr. 60C 4057 Basel BS CH

Christiane Zaborosch

Kontaktperson

christiane.zaborosch@zhaw.ch

ZHAW Christiane Zaborosch Einsiedlerstrasse 31 8820 Wädenswil ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2016-04-30
Date de fin
2018-04-30
Coûts totaux approuvés
CHF 608800.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%